Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Strange. That article lists Ekso Bionics as a Japanese company.
That video, although hilarious, is quite a few years old. Take a look at some of the robots showcased from 2016:
My understanding is that revs and profit have fallen short of being able to pay off interest to date, and another interest payment was due in the immediate future. I certainly don't expect a huge uptick in revenue within the next few quarters, unless something changes drastically. Therefore Dan had to do something to keep his lenders happy.
I'm guessing it was a necessity to secure the 4% interest rate. He's taking the long view in my mind. Short term pain for long term gain. Also having 4 years before principle payments need to be made on the loan takes a big load off the company, to allow them to focus on growth.
Sounds like good news to me! It will take awhile, but over time as FDA builds a database of issues, the statistics will show that the vast majority of issues are from inferior Chinese products, which will let companies manufacturing under strict regulatory procedures (like ECIG) shine!
I think it's a matter of focus.
There are already numerous companies focused solely on the MJ angle, and ECIG would be a fresh starter in the space. This would be difficult for any newcomer to the MJ space, but especially so for ECIG who is already obligated to focus 100% of their resources on nicotine vaping products. They currently don't have enough operating revenue to stay afloat in the vaping space, never mind handling the costs of starting up an MJ division, which would likely require an entirely new product line of devices and liquids.
Looks interesting. Anyone can strap a bunch of plastic to their legs and run through the forest though. LOL
All kidding aside, it would have been nice if they gave a more detailed description in their video of exactly what the unit does, and how it accomplishes it's task. I can surmise based on the name "Kinetic Energy Harvester", but it would be interesting to see more details.
Yes, Many thanks to Rhetorical. Your attention to this stock, and sharing of articles and data is invaluable to new investors and board members just finding their way here for the first time!
The trend is definitely up for EKSO, and I believe that is by design, to not only maintain PPS pressure to stay above the $4 mark, and also to surround the company with hype to coincide with the uplisting (I personally think there's no question that uplisting will happen).
I truly believe the company is headed somewhere big in the next few years, and this is the ground floor! Thomas Looby seems to be doing a great job so far, and is quickly proving his merit with this company.
Just remember... the EKSO GT is the ONLY exoskeleton device approved for stroke rehabilitation, and has a terrific advantage over its competitors in the spinal cord injury area, as it's approved for injuries to a significantly wider range of vertebrae.
All IMHO
The articles and videos speak to how good the product is, and the positive influence they have on patients. This is good to raise awareness as to what EKSO is accomplishing, but in itself is not a key indicator of a good investment. An investor should be looking at the company fundamentals in detail, and taking emotion out of the equation before making an investment decision. To do otherwise is financially irresponsible, and not much different from straight up gambling. At this point the companies sales are improving, but they are still not cash flow positive.
The articles are great for publicity, however they are written to tug on peoples heart-strings, not their purse-strings.
Any serious investor is still going to do his due diligence, and at this point, it makes sense to wait until the Nasdaq uplisting has taken place. If the uplisting is denied, the stock price will likely crater.
I'm struggling with how 100% gung ho you were about this stock prior to the BK despite others providing evidence that might have tempered your enthusiasm, however as soon as the BK was announced you have become the spokesperson for doom and gloom and refuse to even entertain any of the potential silver linings of the situation such as the fact that (to my knowledge) a portion of the company has remained free and clear of the debt restructuring.
Is it likely that this stock will continue to spiral down, yes. Is there the potential to trade on volatility and perhaps claw back some of your money that has been lost? Also yes. Have a little faith!
Does anyone else understand why the big sell off 2 days in a row? I know the financials weren't pristine, but fundamentally I believe the company is headed in the right direction. Am I missing something?
Agreed. It would be nice if Keith updated his recommendation with a new price target.
Right on!
The only downside in that regard is the huge R&D spending they are doing, but they are developing products in 3 different industries, so that is to be expected.
MEDICAL
They are always looking to improve their medical offering, and their work to date has paid off which is evidenced by the only company with an approved exoskeleton designed for stroke patients as well as a huge range of spinal cord injuries. I believe the closest competitor is only approved for rehab of injuries to a couple vertebrae. EKSOD is nearly the entire spine!
INDUSTRIAL
They have created a device to help construction workers lower injuries and fatigue from handling heavy tools for long periods of time. This is just getting off the ground, but they already have a 25 unit test deal with United Rentals for demonstration purposes and to increase awareness. As a member of the construction industry, I think this is a fantastic device, but due to the large upfront cost, it is much better suited as a rental unit to start with. Once a company looks at it's books and realizes how much they are renting it, they can do a cost comparison for themselves and argue for a purchase.
MILITARY
With repeated DARPA contracts under their belt already, they should remain a mainstay of the TALOS program for years to come.
I bought at a bad time last year, and am sitting on roughly a 40% loss compared to current SP levels, but I have utmost faith in this company and their CEO Thomas Looby. Once we are uplisted this should make a steady climb to at least $10-12 on the conservative site. If I had more dry powder to average down right now, I certainly would!
Just a reminder that when this RS happened on May 4th, it closed at $5.915. It has steadily risen ever since. It flattened out last week around $7.00, and now the first day with a drop, and you are all bitter about a failed RS.
This is a minor correction based on the financials released last Friday, and nothing to worry about. The company is strong, and will only get stronger once we uplist and can attract large institutional investors.
I'm with TD Webbroker (Canada), and the adjusted shares with the new 'D' ticker were shown on my platform the day after the RS. I didn't try, but I assumed that meant I could trade it if desired.
My understanding of the conference call was that they had to make a decision to re-submit surgibot for approval, or submit Alf-X for FDA approval, because they cant afford to do both.
It should be clear by now that Alf-X is dead in the water, and has been from day one. It is only slightly less expensive than da vinci, its larger, its based on old technology, and they can't provide the same level of support for it that intuitive surgical can for the da vinci. Therefore it will never EVER take off.
At least the surgibot had the benefit of a low price point to entice smaller medical centers with lower budgets. It will never be a direct competitor to the da vinci, but at the very least it may have been able to carve out a little niche for itself as the best option for healthcare on a budget.
No matter which way you cut it, this company is in deep, deep trouble. My personal opinion however is that pursuing the approval of the Surgibot, and letting Alf-X die is the better of two terrible options.
Based on the huge drop this morning, I guess a lot of people really had their hopes on Surgibot continuing. I don't understand how the company can think that pushing Alf-X is the best route to take. Maybe they just cant swallow their pride over the fact that they over paid for a product based on old technology that nobody wants.
Realistically, I'm so far in the hole that I don't have much of a choice but to stick it out for the long term.
But ideally, I think it's fair to give Dan until Q2 fins. We have improved significantly, but still not out of the woods yet, and Dan also in no uncertain terms said from the last conference call that his focus was going to be on share price moving forward.
I, like many others are losing patience, but Dan never really made any promises to investors regarding share price until this last call.
Thanks (x6)
I agree! Now we just need to pray it holds long enough to be approved for uplist. I know that we need to maintain the $4.00 (or $5.00?) price for at least 30 days before the company can apply, and there are some other factors that go into qualification for the Nasdaq, but does anyone have an idea of how long that process typically takes from application to approval?
Everyone likes to quote the statistic about ecig usage among teens 'exploding' but has anyone ever bothered to do a study on the correlation between increased ecig usage, and decreased combustible cigarette usage among teens? I would not be at all surprised to find out that they largely cancel each other out.
It's not ideal, but at the very least the net result would be kids having a 'healthier' bad habit which is an improvement in my eyes.
I tend to agree with you, in that anyone who has done their proper DD should know that majority of ECIG revenues are from Europe. I just personally don't have much faith in the markets as far as knee jerk, broad-stroke reactions go to news such as this.
I would also agree with you about the fact that nobody knows about the company. It's frustrating to continually see articles being published, and the only brands ever mentioned are those owned by Big Tobacco. Dan needs to realize that it's OK to promote awareness without "pumping" the stock. All it would take is some steady IR/PR re-iterating the strides taken in the last year to turn the ship around, the progress being made, and a few statements regarding the company's strengths, areas of focus, and competitive advantages. That combined with the proven steady (hopefully increasing) revenue being generated by the company would hopefully be enough to attract a few big fish.
Unfortunately many institutional investors will not touch this being on the OTC and also being under $1.
I'm just chalking it up to inexperience (and greed), but i'm so mad at myself for holding onto this POS. I briefly considered selling prior to the FDA announcement, as I suspected that the approval was already baked into the price, and could have walked with a 40% profit. Instead I didn't listen to my gut, and held on, only to lose about 60% when the bad news arrived
ECIG has referenced forthcoming FDA regulations, and mentioned that their juice facility is located in the US, and is manufacturing using approved FDA practices, but that alone doesn't mean we're in the clear. Our products will still have to go through the new approval process (until we find out the predicate date is moved up).
Yes, there is time to discuss, but unless the company is proactive in reassuring the market that this will have a limited impact on our business, ECIG will be treated like any other american based company that will be critically injured by the regulations.
That's where ECIG's new IR and PR work needs to come in play. They need to put something out clarifying how the regulations will affect this company, and reiterate that a majority of our revenue is from Europe where these regs will have no impact!
I really don't know what's running through their heads if they aren't already in the process of crafting something of the sort right now.
I wonder why it's not until the FDA made their ruling that we are starting to see so many articles like this. This is something that everyone in the industry has known since the first mention of the FDA regulation, and yet the media never even bothered to look at this side of the story until after the regulation was passed.
If this isn't evidence that the FDA is in Big Tobacco's pocket, I don't know what is.
Things that make you go 'hmmmm'.
Thanks Longmoney,
I appreciate the insight. I am inclined to agree with you now, although I will admit I had put blinders on in the past when it came to a few of these points. I'm ashamed as an investor to admit that I always thought there was something funny behind the ALF-X acquisition, but never bothered to question it too much
I also want to apologize again for my previous post. I think I spend too much time on message boards, as I find myself hyper-sensitive to people just denouncing stocks with nothing more to back them up other than personal opinions.
It's because your account hasn't updated for the RS yet, just relax. lol
The idea is that if EKSO can successfully uplist to Nasdaq, they will attract institutional investors that otherwise would not be able to touch this stock. Although I am generally not in favor of RS, I tend to think that with this stock, management has the right idea. This is a real company, with a real product, and just received FDA approval for use in applications that no other device is approved for. Also, i'm not 100% sure, but I believe they have also made headway getting approved with insurance providers which is a big step towards more commonplace usage.
With some solid institutional buying, this stock could make some serious headway, or at the very least avoid the slow creep back to pre-RS levels.
Most OTC stocks that go through RS are just garbage companies with garbage offerings which is why they end up back at square one, just with a bunch of pissed off investors owning shares worth a fraction of the price.
Low volume to start with but holding well so far! I was prepared for an immediate crash after the RS.
that's what she said
small fish here. 10,595 shares
The problem is just a lack of awareness/education of the general public. As others pointed out, it's just a vapor cloud. But in addition to that, every single video clip of a massive cloud that you see is from somebody who has purposely assembled their vaping 'rig' with modules, tanks, and batteries specifically designed to produce those large clouds. To many vapers, it's a point of pride for how big their cloud can get.
For those that are specifically using vaping as a smoking cessation device, your stock device such as FIN will work beautifully, and not produce an obnoxious amount of vapor.
The amount of money a customer is willing to spend on their rig is also a factor. If the purpose is to stop smoking, the low cost of a stock rig is likely an attractive draw. To those that have recreational vaping in mind, they are going to want to spend more, as the size of cloud is likely more important to them.
It's great to have a goal of uplisting, but it should be achieved as a result of strengthening the balance sheet. Anything else results in a weak foundation that WILL crumble sooner or later.
No sense in bombarding the market with pumper PR's for no other reason than to artificially increase the share price, as the market will catch on eventually, and you'll be back to square one.
I'm not defending the stock by any means, but i'm well aware that you guys are posting here just for sh*ts and giggles. I would respectfully ask that unless you have something substantial to contribute to the conversation regarding TRXC, please refrain from posting anything.
Now, regarding TRXC, I recall reading a statement saying they had cash on hand to survive roughly to the end of 2016. I suspect they are going to attempt to raise more capital, likely through dilution first. I think it's highly unlikely that they are just going to throw their hands in the air, and say "well, we tried" and shut the doors.
Again, let me be clear I'm not defending the stock. Do I think they will make some reasonable bounce back at any point in the near future? not a chance. But do I think they will try everything in their power to stick it out and keep their heads above water? Absolutely. That being said, if you are convinced they will declare BK in that time frame, please provide a reasonable and well thought out explanation to support your opinion.
I was surprised to see something positive on mainstream media finally regarding ecigs:
http://globalnews.ca/video/2669285/british-doctors-say-e-cigarettes-effective-to-quit-smoking
I'm sure there's many that would disagree with me, but the way I see it is that from SUNEQ's books, assets are higher than liabilities. This doesn't however take into account the true value of a number of their assets. Just because SUNEQ paid $X Million for an asset, doesn't mean that it's currently worth that much. That being said, I think the asset value being reported is higher than true value.
Nobody is going to know for awhile what the real values are, but I really wouldn't be surprised to learn that the liabilities far outweigh the assets at the end of the day. Just keep in mind, that alone does not guarantee the company's insolvency. It's all about cash flow. As long as they can continue to drive enough revenue to cover operating expenses and debt repayments, they should be able to stay in business. It's obvious right now that they have to sell a few assets to make this possible, but this should be enough to keep the lights on.
All IMHO
not huge volume, but up 2 cents so far today. I suspect it can be attributed to the standard run up before earnings, but one can always dream that its because word is getting out about the positives here.
You have any evidence of this?
I'm super long ecig, but like many others here, i'm running out of patience with Dan regarding the share price. I realize he's a great business leader. One of the best out there, but this is his first foray into an OTC company, and he needs to treat it as such until we are able to uplist. I don't see any other way out of the sub-dollar hole we are in.
Doesn't he? Although I think his projections about where the company is headed are a little optimistic, I am more inclined to believe his opinions regarding hospital admin having the final say on what is purchased for each hospital based on financial decisions.
I'm sure surgeons recommendations would be taken into account in some capacity, but if admin crunches the numbers and finds out that they can do 4 times the procedures with reduced liability because they can buy 4 surgibots for every davinci, I am inclined to believe that is what they will purchase.
If you have a legitimate reason why you think he has no idea what he is talking about, lets hear it. Just saying you don't agree without offering an intelligent and logical opposition to his stance, contributes absolutely nothing to the conversation, and is of no value to anyone here.